Search results for " STEATOSIS"

showing 10 items of 63 documents

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C

2013

SUMMARY. Soluble CD36 (sCD36) plasma levels, a known marker of cardiometabolic disorders, are associated with surrogate markers of steatosis, while experimental and human studies show a link between CD36 expression in the liver and steatosis. In a cohort of patients with genotype 1 chronic hepatitis C (G1 CHC), we tested the association of sCD36 plasma levels with host and viral factors and sustained virological response (SVR). One hundred and seventy-five consecutive biopsy-proven patients were studied. sCD36 plasma levels were assessed by an in-house ELISA. All biopsies were scored by one pathologist for staging and grading (Scheuer) and graded for steatosis, which was considered moderate…

AdultCD36 AntigensMaleGenotypeBiopsyEnzyme-Linked Immunosorbent AssayLIVER FIBROSISHepacivirusCHRONIC HEPATITIS CAntigens CD36Settore MED/08 - Anatomia PatologicaAntiviral AgentsSeverity of Illness IndexPlasmaRibavirinHumansHEPATIC STEATOSISAgedSettore MED/12 - GastroenterologiaHepatitis C ChronicMiddle AgedFatty LiverLiverBiological MarkersFemaleInterferonsCD36 HCV steatosisBiomarkersINSULIN RESISTANCE
researchProduct

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

2007

Aims To assess whether host metabolic factors influence the degree of hepatic steatosis and fibrosis in patients infected with hepatitis C virus, and to evaluate the impact of anti-viral therapy on insulin resistance and serum levels of adipocytokines. Methods Clinical and biochemical features, anthropometrical characteristics, and levels of fasting insulin, leptin, adiponectin and resistin were measured in ‘naı¨ve’ patients with chronic hepatitis C, before, during and after therapy with Peg-Interferon-alpha 2a plus Ribavirin. Results Forty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years; 62.5% genotype-1). Body mass index was 26.4 4.0 kg/m2 , and visceral obesity was present in 24…

AdultLiver CirrhosisMaleInterferon-alphahcv steatosisHepatitis C ChronicInterferon alpha-2Intra-Abdominal FatMiddle AgedAntiviral AgentsRecombinant ProteinsFatty LiverRibavirinAdipocytesHumansFemaleObesityInsulin ResistanceAlimentary pharmacologytherapeutics
researchProduct

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the ev…

2013

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according t…

AdultLiver CirrhosisMalemedicine.medical_specialtyConcordanceBiopsySettore MED/08 - Anatomia PatologicaSeverity of Illness IndexFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSAF steatosis activity fibrosis.Nonalcoholic fatty liver diseaseBiopsyNAS nonalcoholic steatohepatitis activity scoremedicineHumansAgedObserver VariationHepatologymedicine.diagnostic_testbusiness.industryFatty liverGold standard (test)HepatologyMiddle Agedmedicine.diseaseFatty LiverLiverNASH nonalcoholic steatohepatitiDisease ProgressionFemaleNAFLD nonalcoholic fatty liver diseaseSteatosisbusinessAlgorithmAlgorithmsHepatology (Baltimore, Md.)
researchProduct

Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 I…

2013

Background & Aims: Few studies have evaluated the accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C. We assessed its accuracy in detecting steatosis and factors that affect its diagnostic performance in consecutive patients with chronic hepatitis C virus genotype 1infection. Methods: We analyzed data from 515 patients with chronic hepatitis C, confirmed by liver biopsy, assessing anthropometric, biochemical, metabolic, virologic, and ultrasonography features. Transient elastography was performed to measure liver stiffness. Steatosis was identified with ultrasonography based on detection of a bright liver echo pattern. Results: Ultrasonography identified…

AdultMalemedicine.medical_specialtyCirrhosisGenotypeHepatitis C virusHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyBody Mass IndexPredictive Value of TestsInternal medicinemedicineHumansAgedSettore MED/12 - Gastroenterologiahcv fibrosis fibroscan steatosis histologyHepatologymedicine.diagnostic_testDiagnostic Tests Routinebusiness.industryGastroenterologyOdds ratioHepatitis C ChronicMiddle Agedmedicine.diseaseElasticityConfidence intervalFatty LiverLiverLiver biopsyElasticity Imaging TechniquesFemaleSteatosisbusinessTransient elastographyBody mass indexClinical Gastroenterology and Hepatology
researchProduct

Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C

2013

Patients with genotype 1 chronic hepatitis C (G1 CHC) frequently develop steatosis and insulin resistance (IR), caused by metabolic and viral factors. These accelerate the progression of liver disease and reduce the response to therapy. A sustained virologic response (SVR) to therapy in patients with G1 CHC is associated strongly with polymorphisms near the interleukin-28B (IL28B) gene, but the interaction between IL28B genotype and IR, and their combined effects on SVR, have not been defined. We tested the association between the IL28B rs12979860 single-nucleotide polymorphism and metabolic features, including IR, and evaluated their effects on SVR.We performed genotype analysis of IL28B r…

AdultMalemedicine.medical_specialtyGenotypeHepacivirusHepatitis C virusSingle-nucleotide polymorphismHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideGastroenterologyCohort StudiesLiver diseaseInsulin resistanceInternal medicineGenotypemedicineHumansAgedinsulin resistance steatosis interleukin-28B sustained virologic responseHepatologybiologybusiness.industryInterleukinsGastroenterologyHepatitis C ChronicMiddle AgedViral Loadmedicine.diseasebiology.organism_classificationTreatment OutcomeInterleukin 28BImmunologyMetabolomeRNA ViralFemaleInterferonsInsulin ResistanceSteatosisbusinessClinical Gastroenterology and Hepatology
researchProduct

Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia.

2008

Aim To evaluate the reliability of the bright liver (BL) echo pattern on ultrasound to detect histological steatosis in chronic cryptogenic hypertransaminasaemia (CCH) and hepatitis C virus (HCV)-related forms of hypertransaminasaemia. Materials and methods One hundred and fifty patients, 54 with CCH and 96 with HCV hypertransaminasaemia (76 genotype 1/2 and 20 genotype 3), were enrolled. Histological steatosis was measured as the percentage of hepatocytes involved. The reliability of the BL sign was estimated using the sensitivity, specificity, positive and negative predictive values. Results Histological steatosis was present in 102/150 patients (68%) divided into 59/96 (62%) in the HCV g…

AdultMalemedicine.medical_specialtyHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologySensitivity and SpecificityInternal medicineStatistical significanceGenotypemedicinePrevalenceHumansRadiology Nuclear Medicine and imagingProspective StudiesUltrasonography Doppler ColorTransaminasesHepatitis Chronicbiologybusiness.industryFatty liverGeneral MedicineHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CConfidence intervalFatty LiverItalyLiverHepatocytesFemalebright liver ultrasound steatosis cryptogenic hypertransaminasaemiaSteatosisbusinessBiomarkersClinical radiology
researchProduct

High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steato…

2011

Abstract Background and aim To investigate the hepatic expression of retinol-binding protein-4 (RBP4) in chronic hepatitis C (CHC) and nonalcoholic steatohepatitis (NASH) patients, and its association with biochemical and histological patterns of liver damage. Materials and methods Sixty-six genotype 1 CHC and 32 NASH patients were tested for hepatic RBP4 expression. Liver expression at immunostaining was scored as 0 (slight), 1 (mild), 2 (moderate), and 3 (intense). In addition, the mRNA and the quantitative protein expressions of RBP4 were tested by PCR and by western blot, respectively, in 12 NASH and 28 CHC patients. Twelve subjects undergoing elective cholecystectomy served as controls…

AdultMalemedicine.medical_specialtyLogistic ModelFibrosiHepatitis C virusInflammationSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyBody Mass IndexWestern blotFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineGenotypeMedicineHumansAge FactorRNA MessengerHEPATIC STEATOSISRetinol binding protein 4Settore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbiologyNONALCOHOLIC STEATOHEPATITISbusiness.industryGastroenterologyAge FactorsHEPATITIS C VIRUSHepatitis C ChronicMiddle Agedmedicine.diseaseFibrosisFatty LiverLogistic Modelsbiology.proteinmedicine.symptomSteatosisInsulin ResistanceWaist CircumferenceRetinol binding protein-4businessRetinol-Binding Proteins PlasmaImmunostainingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

2006

: Background/Aim: Liver steatosis (LS) has been variably associated with chronic hepatitis C (CHC) but whether it affects sustained virological response to antiviral treatment and by what mechanisms is a question still under debate, at least for some genotypes. The aim of this work was to assess the frequency of LS, its relationship with host and viral factors and to what extent it can influence the response to antiviral combination therapy with pegylated interferon (INF)+ribavirin in a group of patients with CHC from a single center. Patients: One hundred and twelve patients with histologically proven CHC were treated with Peg INF-α 2a 180 μg a week subcutaneously for 48 weeks plus ribavir…

AdultMalemedicine.medical_specialtyPathologyAgingCombination therapyGenotypeHepatitis C virusantiviral treatmentHepacivirusInterferon alpha-2Single Centermedicine.disease_causeGastroenterologyAntiviral AgentsSeverity of Illness IndexBody Mass IndexPolyethylene Glycolsliver steatosischemistry.chemical_compoundPegylated interferonInternal medicineGenotypeRibavirinmedicinechronic hepatitis CHumansAspartate AminotransferasesHepatologybusiness.industryRibavirinInterferon-alphaAlanine Transaminasegamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsFatty LiverTreatment OutcomechemistryLiverDrug Therapy CombinationFemaleSteatosisbusinessBody mass indexmedicine.drugLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Upregulation of liver VLDL receptor and FAT/CD36 expressions in LDLR-/- apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid

2006

International audience; This study explores the mechanisms responsible for the fatty liver setup in mice fed trans-10,cis-12 conjugated linoleic acid (t10c12 CLA), hypothesizing that an induction of low density lipoprotein receptor (LDLR) expression is associated with lipid accumulation. To this end, the effects of t10c12 CLA treatment on lipid parameters, serum lipoproteins, and expression of liver lipid receptors were measured in LDLR(-/-) apoB(100/100) mice as a model of human familial hypercholesterolemia itself depleted of LDLR. Mice were fed t10c12 CLA over 2 or 4 weeks. We first observed that the treatment induced liver steatosis, even in the absence of LDLR. Mice treated for 2 weeks…

CD36 AntigensMaleVery low-density lipoproteinTRANSLOCASECD36RECEPTEUR SCAVENGER[SDV]Life Sciences [q-bio]FATTY ACID TRANSLOCASE030204 cardiovascular system & hematologyBiochemistryMice0302 clinical medicineEndocrinologyLinoleic Acids ConjugatedMice Knockout0303 health sciencesLipoprotein lipaselipoprotéinebiologyacide grasrécepteur d'hormoneChemistryFatty liverFatty Acidsfood and beveragesHEPATIC LIPASELipidsLOW DENSITY LIPOPROTEIN RECEPTOR3. Good healthUp-RegulationLiverSCAVENGER RECEPTOR CLASS B TYPE ILIVER STEATOSIS;LOW DENSITY LIPOPROTEIN RECEPTOR;TRIGLYCERIDE;LIPOATROPHY;LIPOPROTEIN;FATTY ACID TRANSLOCASE;VERY LOW DENSITY LIPOPROTEIN RECEPTOR;HEPATIC LIPASE;LIPOPROTEIN LIPASE;LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN;SCAVENGER RECEPTOR CLASS B TYPE I;LIPOATROPHIE;TRANSLOCASE;LIPASE HEPATIQUE;RECEPTEUR SCAVENGERApolipoprotein B-100lipoprotéine lipaseTRIGLYCERIDElipids (amino acids peptides and proteins)Oxidation-Reductionmedicine.medical_specialtyLIPASE HEPATIQUELipolysisVLDL receptorMice Transgenicacide linoléique conjugué03 medical and health sciencesstéatose hépatiqueInternal medicineLIVER STEATOSISmedicineLIPOPROTEIN LIPASEAnimalsRNA Messengerlipoprotéine de faible densite030304 developmental biologyLOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEINnutritional and metabolic diseasesCell Biologymedicine.diseaseLipid MetabolismLIPOATROPHYDietary FatsEndocrinologyLIPOPROTEINReceptors LDLVERY LOW DENSITY LIPOPROTEIN RECEPTORLIPOATROPHIELDL receptorbiology.proteinacide gras transHepatic lipaseLipoprotein
researchProduct